drugset
drugset / Trial / NCT01374373

Epoetin Alfa (Hemax®) Phase IV Study in Chemotherapy Induced Anemia

NCT01374373 ↗

Phase 4 Completed 30 enrolled Bio Sidus SA IC RESEARCH GROUP · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess safety and efficacy of weekly epoetin alfa (Hemax® ) administered for 12 weeks in patients with non curable solid tumors or lymphoma with anemia (hemoglobin \< 10g/dl) undergoing palliative care chemotherapy.

Timeline

Start
2011-06
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 40000 iu Subcutaneous
Subject epoetin alfa Protein / enzyme biologic 60000 iu Subcutaneous

Indications

chemotherapy-induced toxicity